Remove

Approved for use through 07/31/2008 CMS D651-0321.

U.S. Patent and Trachmask Office, U.S. D6FATNENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10393700		
	Filing Date		2006-05-11		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Eric I		Lavoie		
Not for submission under 37 CFR 1.99)	Art Unit				
not for Gabinission and or or it is any	Examiner Name				
	Attorney Docket Numb	er	0056225-000001		

U.S.PATENTS

			U.S.PATENTS					WEITHOVE			
		Kind Code ¹	Issue [Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	6536283	B1	2003-0	3-25	Hatley					
	2	6222897	B1	2001-0	4-24	Haffey et al.					
	3	4331034		1982-0	5-25	Takeda et al.					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date Name of Patentee or Application of cited Document			Releva		Lines when ges or Rele		
	1	20040020298	A1	2004-0	2-05	Swerling et al.					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d buttor	Add		
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² i Code ⁴		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevan	Ts
	1	1174352	CA			1984-09-11	Livingston				ln

	2	2097	583	CA		1993-12-02	Latimer			
	3	4123	196	EP	A2	1991-02-13	Gugel			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examinor Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.								Τs		
	1	International Search Report								
	2	International Prelimnary Examination Report								
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examin	Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a										

See Kins Codes of USPTO Patent Documents at swer_USPTO_GOV/ or MPEP 901.04. * Enter of tions that issued the document, by the two-left or gold or WIPO Standard S13... * For Laprantee patent counters, the ancidation of the year of the region of the Emport man precise or the serial replant document. * Kind of document by the appropriate symbols as andicated on the document under WIPO Standard S11.6 if possible. * Applicant is to place a check man's here if Emploit insurance instruction as attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595788	
Filing Date		2006-05-11	
First Named Inventor	Eric Lavoie		
Art Unit			
Examiner Name			
Attorney Docket Number		0056225-000001	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/WCRowland/	Date (YYYY-MM-DD)	2006-05-13
Name/Print	William C. Rowland	Registration Number	30888

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bast 1436, Alexandria, V.32.11.445. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.